Request a Rep
AML is a deadly disease with a high risk of relapse even after achieving a CR or CRi1
Continued treatment with ONUREG® may provide a path to extending OS for AML patients in first remission who do not receive a transplant7,8
More than half of AML patients do not proceed to HSCT; reasons for not receiving transplant may include9,12-14:
For certain patients age ≥60